Under the terms of the agreement, Exelixis will pay Storm an upfront fee of $17 million to license two of Storm's discovery programs targeting RNA-modifying enzymes. Proceeds will also help fund discovery research activities conducted or managed by Storm.

The collaboration will focus initially on a protein called RNA-specific adenosine deaminase 1 (ADAR1) to deliver small-molecule clinical candidate compounds discovered using Storm's proprietary RNA-modifying enzyme drug discovery platform.

Exelixis, Invenra expand cancer antibody collaboration
Exelixis has expanded its discovery and licensing collaboration with Invenra to include an additional 20 oncology targets. The expanded collaboration...

Exelixis to acquire GamaMabs' AMHR2 antibody tech
Exelixis will acquire GamaMabs' anti-Müllerian hormone receptor type 2 (AMHR2) antibody technology for $5 million.

RNA editing enzyme ADAR1 helps cancer cells proliferate
Researchers have discovered that an isoform of the RNA editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) is responsible for regulating genome...

Exelixis licenses antibody panel from WuXi Biologics
Exelixis and WuXi Biologics have entered into an exclusive license agreement to support the expansion of Exelixis' oncology pipeline.

Researchers identify 'ancient' DNA weapons against cancer
Researchers have identified silent ancient DNA elements buried in the human genome that when "reactivated" can initiate an immune response toward cancer...